WhisperX tag archive

#Cancer Research

This page collects WhisperX intelligence signals tagged #Cancer Research. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.

Latest Signals (4)

The Lab · 2026-04-01 09:27:03 · ZeroHedge

1. Major Study: Nicotine Vaping 'Likely Carcinogenic,' Poses Direct Cancer Risk

A landmark study from the University of New South Wales delivers a stark warning: nicotine-based e-cigarettes are likely carcinogenic to humans, directly linked to lung and oral cancers. Published in the journal *Carcinogenesis*, the research synthesizes human studies, animal experiments, and lab tests to build a compe...

The Lab · 2026-04-13 13:22:51 · Seeking Alpha

2. Regeneron and Telix Forge Strategic Alliance in High-Stakes Radiopharmaceutical Arena

Regeneron Pharmaceuticals has entered into a significant collaboration with Telix Pharmaceuticals, marking a major strategic move into the rapidly evolving field of targeted radiopharmaceutical therapies. This deal signals a convergence of Regeneron's established prowess in antibody development with Telix's specialized...

The Lab · 2026-04-14 20:22:27 · Retraction Watch

3. BMJ's Journal of Medical Genetics Retracts 7 Papers in Special Issue Over 'Compromised' Peer Review

A major genetics journal has retracted nearly an entire special issue, citing an 'irreparably compromised' peer review process and 'improbable device use.' The BMJ's Journal of Medical Genetics pulled seven of the eight papers from its 2019 special issue, including an editorial that primarily referenced the now-retract...

The Lab · 2026-04-21 22:52:52 · STAT News

4. Revolution Medicines' KRAS Drug Posts Stunning Survival Data at AACR, NCI Director Addresses Funding Fears

The American Association for Cancer Research (AACR) annual meeting has been dominated by a single, stunning data release. Biotechnology firm Revolution Medicines presented results showing its experimental KRAS-targeting drug, daraxonrasib, more than doubled survival in second-line pancreatic cancer patients compared to...